Literature DB >> 19608627

The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms.

Isabella Manni1, Simona Artuso, Silvia Careccia, Maria Giulia Rizzo, Renato Baserga, Giulia Piaggio, Ada Sacchi.   

Abstract

MicroRNAs (miRs) are 21- to 23-nucleotide RNA molecules that regulate the stability or translational efficiency of target messenger RNAs of proteins involved in cell growth and apoptosis. miR-92 is part of the mir-17-92 cluster, which comprises members with an effect on cell proliferation. However, the role of miR-92 is unknown, and its targets have not been identified. Here, we describe a mechanism through which miR-92 contributes to regulate cell proliferation. Using a miR-92 synthetic double-strand oligonucleotide, we demonstrate that miR-92 increases 32D myeloid cell proliferation and 5-bromo-2-deoxyuridine (BrdU) incorporation and inhibits cell death. The effect is miR-92 specific since the miR-92 antagomir inhibits cell proliferation. Moreover, we show that miR-92 acts by modulating p63-isoform abundance through down-regulatation of endogenous DeltaNp63beta. Using luciferase reporters containing p63 3'UTR fragments with wild-type or mutant miR-92 complementary sites, we demonstrate that the wild-type 3'UTR is a direct target of miR-92. Finally, we observed that a miR-92-resistant DeltaNp63beta isoform (without 3'UTR) inhibits cell proliferation and parallels the effect of the antagomir. We conclude that one of the molecular mechanisms through which miR-92 increases cell proliferation is by negative regulation of an isoform of the cell-cycle regulator p63.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608627     DOI: 10.1096/fj.09-131847

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  46 in total

Review 1.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

Review 2.  The microRNA-17-92 family of microRNA clusters in development and disease.

Authors:  Carla P Concepcion; Ciro Bonetti; Andrea Ventura
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

3.  Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer.

Authors:  Tong Zhou; Guangjun Zhang; Zuoliang Liu; Shusen Xia; Hongpeng Tian
Journal:  Int J Colorectal Dis       Date:  2012-07-07       Impact factor: 2.571

Review 4.  Regulating miRNA by natural agents as a new strategy for cancer treatment.

Authors:  Sajiv Sethi; Yiwei Li; Fazlul H Sarkar
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

5.  Blockage of miR-92a-3p with locked nucleic acid induces apoptosis and prevents cell proliferation in human acute megakaryoblastic leukemia.

Authors:  M Sharifi; R Salehi
Journal:  Cancer Gene Ther       Date:  2015-12-11       Impact factor: 5.987

6.  Tumorigenicity of the miR-17-92 cluster distilled.

Authors:  Gijs van Haaften; Reuven Agami
Journal:  Genes Dev       Date:  2010-01-01       Impact factor: 11.361

7.  Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium.

Authors:  Yun Fang; Peter F Davies
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-19       Impact factor: 8.311

8.  Role of p63 in Development, Tumorigenesis and Cancer Progression.

Authors:  Johann Bergholz; Zhi-Xiong Xiao
Journal:  Cancer Microenviron       Date:  2012-07-31

9.  The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex.

Authors:  Lakshmanane Boominathan
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

10.  miR-17-92 cluster: ups and downs in cancer and aging.

Authors:  Johannes Grillari; Matthias Hackl; Regina Grillari-Voglauer
Journal:  Biogerontology       Date:  2010-05-01       Impact factor: 4.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.